These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12187956)

  • 1. Immunohistochemical markers for prognosis of anaplastic astrocytomas.
    Korshunov A; Golanov A; Sycheva R
    J Neurooncol; 2002 Jul; 58(3):203-15. PubMed ID: 12187956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas.
    Kirla RM; Haapasalo HK; Kalimo H; Salminen EK
    Cancer; 2003 Feb; 97(3):644-8. PubMed ID: 12548606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.
    Aldape KD; Ballman K; Furth A; Buckner JC; Giannini C; Burger PC; Scheithauer BW; Jenkins RB; James CD
    J Neuropathol Exp Neurol; 2004 Jul; 63(7):700-7. PubMed ID: 15290895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
    Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M
    Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.
    Rodriguez EF; Scheithauer BW; Giannini C; Rynearson A; Cen L; Hoesley B; Gilmer-Flynn H; Sarkaria JN; Jenkins S; Long J; Rodriguez FJ
    Acta Neuropathol; 2011 Mar; 121(3):407-20. PubMed ID: 21113787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of gemistocytes in astrocytoma progression.
    Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
    Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
    Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
    Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression.
    Frankel B; Longo SL; Leach C; Canute GW; Ryken TC
    J Neurooncol; 2002 Aug; 59(1):27-34. PubMed ID: 12222835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
    Korshunov A; Golanov A; Sycheva R
    J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and mutation analysis of the p53 gene in astrocytoma.
    Hwang SL; Hong YR; Sy WD; Chai CY; Lin HJ; Howng SL
    J Formos Med Assoc; 1999 Jan; 98(1):31-8. PubMed ID: 10063271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors.
    Khalid H; Shibata S; Kishikawa M; Yasunaga A; Iseki M; Hiura T
    Cancer; 1997 Dec; 80(11):2133-40. PubMed ID: 9392336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis.
    Cummings TJ; Provenzale JM; Hunter SB; Friedman AH; Klintworth GK; Bigner SH; McLendon RE
    Acta Neuropathol; 2000 May; 99(5):563-70. PubMed ID: 10805102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases.
    Ho DM; Wong TT; Hsu CY; Ting LT; Chiang H
    Cancer; 1998 Jun; 82(12):2459-66. PubMed ID: 9635540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults.
    Matsumoto T; Fujii T; Yabe M; Oka K; Hoshi T; Sato K
    Histopathology; 1998 Nov; 33(5):446-52. PubMed ID: 9839169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleomorphic xanthoastrocytomas: immunohistochemistry, grading and clinico-pathologic correlations. An analysis of 34 cases from a single Institute.
    Korshunov A; Golanov A
    J Neurooncol; 2001 Mar; 52(1):63-72. PubMed ID: 11451204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocalyxin expression in malignant astrocytic tumors.
    Hayatsu N; Kaneko MK; Mishima K; Nishikawa R; Matsutani M; Price JE; Kato Y
    Biochem Biophys Res Commun; 2008 Sep; 374(2):394-8. PubMed ID: 18639524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
    Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
    Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.